Medicare Walks Back Proposed Payment Policy For 505(b)(2) Physician Administered Drugs
Executive Summary
CMS acknowledges stakeholders may need more details about the plan before it is finalized and a delay will give the agency more time to ‘consider the issue.’
You may also be interested in...
Drug Rebates, Impact On Premiums Must Be Disclosed Under COVID Stimulus Law
Medicare Part B payment loopholes also targeted in law, and Medicare Part D plans will need to offer real-time benefit tools for prescriber-patient decision making.
Medicare Proposed Part B Payment Policy For 505(b)(2) Drugs Is Illegal, Biopharma Argues
BMS, Biogen and other urge CMS to rescind its proposal to reimburse Part B drugs approved under section 505(b)(2) as multiple source products. The proposal would target one relatively small but growing part of Medicare Rx spending and reflects CMS’ ongoing concern with fast rising costs in the program
Medicare’s Final Coverage Decision On Alzheimer’s Drugs: Thoughts From A Former CMS Chief
Mark McClellan discusses whether CMS’s pending final version of the Medicare national coverage determination on Alzheimer’s drugs might change from the draft and whether the decision should be viewed as a precedent for drugs granted accelerated approvals.